Amedeo Smart

Free Medical Literature Service

 

Amedeo

Prostate Cancer
  Free Subscription

Articles published in
Br J Cancer
    October 2025
  1. CHANG YH, Bresnahan ST, Taylor Head S, Harrison TA, et al
    Isoform-level analyses of 6 cancers uncover extensive genetic risk mechanisms undetected at the gene-level.
    Br J Cancer. 2025;133:874-885.
    >> Share

    September 2025
  2. MAY M, Gilfrich C, Enzinger B, Brookman-May S, et al
    Exercise oncology in prostate cancer: from observational insight to prescriptive precision.
    Br J Cancer. 2025 Sep 16. doi: 10.1038/s41416-025-03205.
    >> Share

  3. HUANG H, Benzonana LL, Zhao H, Watts HR, et al
    Correction to: Prostate cancer cell malignancy via modulation of HIF-1alpha pathway with isoflurane and propofol alone and in combination.
    Br J Cancer. 2025 Sep 5. doi: 10.1038/s41416-025-03175.
    >> Share

    July 2025
  4. AN KY, Jeon JY, Arthuso FZ, Wang Q, et al
    Postdiagnosis physical activity is associated with improved survival in prostate cancer patients treated with surgery but not with radiation therapy.
    Br J Cancer. 2025 Jul 23. doi: 10.1038/s41416-025-03123.
    >> Share

  5. FLAHERTY RL, Falcinelli M, Hesketh AR, Patel BA, et al
    Biomarkers of psychological stress are associated with increased susceptibility to the development of breast and prostate cancer in BRCA1/2 mutation carriers.
    Br J Cancer. 2025 Jul 2. doi: 10.1038/s41416-025-03085.
    >> Share

    April 2025
  6. LI X, Mamouni K, Zhao R, Bai L, et al
    Novel Skp1 inhibitor has potent preclinical efficacy against castration-resistant prostate cancer.
    Br J Cancer. 2025 Apr 19. doi: 10.1038/s41416-025-02993.
    >> Share

  7. HARTLEY A, Galbraith LCA, Shaw R, Tibbo A, et al
    Loss of ARID1A accelerates prostate tumourigenesis with a proliferative collagen-poor phenotype through co-operation with AP1 subunit cFos.
    Br J Cancer. 2025;132:502-512.
    >> Share

    March 2025
  8. LI GX, Ma B, Zhang S, Liu R, et al
    EphB4-ephrin-B2 are targets in castration resistant prostate cancer.
    Br J Cancer. 2025 Mar 5. doi: 10.1038/s41416-025-02942.
    >> Share

  9. O'SULLIVAN JM, Heinrich D, Castro E, George S, et al
    Alkaline phosphatase decline and pain response as predictors of overall survival benefit in patients treated with radium-223: a post hoc analysis of the REASSURE study.
    Br J Cancer. 2025;132:354-360.
    >> Share

    February 2025
  10. LIN SC, Cheng YS, Lin YS, Nguyen TMH, et al
    The long noncoding RNA lncZBTB10 facilitates AR function via S-palmitoylation to promote prostate cancer progression and abiraterone resistance.
    Br J Cancer. 2025 Feb 16. doi: 10.1038/s41416-025-02938.
    >> Share

  11. VAN DER KLEIJ MBA, Meertens M, Groenland SL, Kordes S, et al
    Feasibility and efficacy of therapeutic drug monitoring of abiraterone in metastatic castration resistant prostate cancer patients.
    Br J Cancer. 2025 Feb 11. doi: 10.1038/s41416-025-02954.
    >> Share

  12. WANG R, Wang S, Mi Y, Huang T, et al
    Elevated serum levels of GPX4, NDUFS4, PRDX5, and TXNRD2 as predictive biomarkers for castration resistance in prostate cancer patients: an exploratory study.
    Br J Cancer. 2025 Feb 3. doi: 10.1038/s41416-025-02947.
    >> Share

    December 2024
  13. LUO L, Wang R, Bai L, Shang J, et al
    The accuracy of fluorine 18-labelled prostate-specific membrane antigen PET/CT and MRI for diagnosis of prostate cancer in PSA grey zone.
    Br J Cancer. 2024 Dec 19. doi: 10.1038/s41416-024-02934.
    >> Share

  14. LIU C, Reger M, Fan H, Wang J, et al
    Dietary intake of isoflavones and coumestrol and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian cancer screening trial.
    Br J Cancer. 2024 Dec 16. doi: 10.1038/s41416-024-02929.
    >> Share

  15. CHEN M, Zhou S, He X, Wen H, et al
    Identification of diagnostic biomarkers in prostate cancer-related fatigue by construction of predictive models and experimental validation.
    Br J Cancer. 2024 Dec 15. doi: 10.1038/s41416-024-02922.
    >> Share

    October 2024
  16. RAHMAN R, Rahaman MH, Hanson AR, Choo N, et al
    Author Correction: CDK9 inhibition constrains multiple oncogenic transcriptional and epigenetic pathways in prostate cancer.
    Br J Cancer. 2024 Oct 24. doi: 10.1038/s41416-024-02862.
    >> Share

  17. SHEN M, Garcia-Marques F, Muruganantham A, Liu S, et al
    Identification of a 5-gene signature panel for the prediction of prostate cancer progression.
    Br J Cancer. 2024 Oct 14. doi: 10.1038/s41416-024-02854.
    >> Share

    September 2024
  18. CHOW ST, Fan J, Zhang X, Wang Y, et al
    Nuclear receptor TLX functions to promote cancer stemness and EMT in prostate cancer via its direct transactivation of CD44 and stem cell-regulatory transcription factors.
    Br J Cancer. 2024 Sep 26. doi: 10.1038/s41416-024-02843.
    >> Share

  19. WANG T, Wang X, Ding G, Liu H, et al
    Efficacy and safety evaluation of androgen deprivation therapy-based combinations for metastatic castration-sensitive prostate cancer: a systematic review and network meta-analysis.
    Br J Cancer. 2024 Sep 2. doi: 10.1038/s41416-024-02823.
    >> Share

    August 2024
  20. NTURUBIKA BD, Guardia CM, Gershlick DC, Logan JM, et al
    Altered expression of vesicular trafficking machinery in prostate cancer affects lysosomal dynamics and provides insight into the underlying biology and disease progression.
    Br J Cancer. 2024 Aug 31. doi: 10.1038/s41416-024-02829.
    >> Share

  21. RAHMAN R, Rahaman MH, Hanson AR, Choo N, et al
    CDK9 inhibition inhibits multiple oncogenic transcriptional and epigenetic pathways in prostate cancer.
    Br J Cancer. 2024 Aug 8. doi: 10.1038/s41416-024-02810.
    >> Share

    July 2024
  22. LIN BB, Huang Q, Yan B, Liu M, et al
    An 18-gene signature of recurrence-associated endothelial cells predicts tumor progression and castration resistance in prostate cancer.
    Br J Cancer. 2024 Jul 12. doi: 10.1038/s41416-024-02761.
    >> Share

  23. PUJANA-VAQUERIZO M, Bozal-Basterra L, Carracedo A
    Metabolic adaptations in prostate cancer.
    Br J Cancer. 2024 Jul 5. doi: 10.1038/s41416-024-02762.
    >> Share

  24. CYLL K, Skaaheim Haug E, Pradhan M, Vlatkovic L, et al
    DNA ploidy and PTEN as biomarkers for predicting aggressive disease in prostate cancer patients under active surveillance.
    Br J Cancer. 2024 Jul 3. doi: 10.1038/s41416-024-02780.
    >> Share

    June 2024
  25. ARMAKOLAS A, Alevizopoulos N, Stathaki M, Petraki C, et al
    Anti-PEc: Development of a novel monoclonal antibody against prostate cancer.
    Br J Cancer. 2024 Jun 20. doi: 10.1038/s41416-024-02713.
    >> Share

    March 2024
  26. ZHANG Y, Stopsack KH, Wu K, Song M, et al
    Multivitamin use after diagnosis and prostate cancer survival among men with nonmetastatic prostate cancer.
    Br J Cancer. 2024 Mar 15. doi: 10.1038/s41416-024-02651.
    >> Share

  27. GNANAPRAGASAM V
    Shifting the paradigm in the management of early prostate cancer.
    Br J Cancer. 2024 Mar 6. doi: 10.1038/s41416-024-02641.
    >> Share

    February 2024
  28. EBERLEIN C, Williamson SC, Hopcroft L, Ros S, et al
    Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer.
    Br J Cancer. 2024 Feb 23. doi: 10.1038/s41416-024-02614.
    >> Share

  29. LIU Q, Zhang Y, Vaselkiv JB, Mucci LA, et al
    A prospective study of birth weight and prostate cancer risk and mortality in the Health Professionals Follow-up Study.
    Br J Cancer. 2024 Feb 22. doi: 10.1038/s41416-024-02593.
    >> Share

  30. CONSTANTIN TA, Varela-Carver A, Greenland KK, de Almeida GS, et al
    Correction: The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer.
    Br J Cancer. 2024 Feb 14. doi: 10.1038/s41416-024-02606.
    >> Share

  31. O'MALLEY DE, Raspin K, Melton PE, Burdon KP, et al
    Acquired copy number variation in prostate tumours: a review of common somatic copy number alterations, how they are formed and their clinical utility.
    Br J Cancer. 2024;130:347-357.
    >> Share

    January 2024
  32. MAH CY, Nguyen ADT, Niijima T, Helm M, et al
    Peroxisomal beta-oxidation enzyme, DECR2, regulates lipid metabolism and promotes treatment resistance in advanced prostate cancer.
    Br J Cancer. 2024 Jan 12. doi: 10.1038/s41416-023-02557.
    >> Share

    December 2023
  33. FRITZ J, Jochems SHJ, Bjorge T, Wood AM, et al
    Body mass index, triglyceride-glucose index, and prostate cancer death: a mediation analysis in eight European cohorts.
    Br J Cancer. 2023 Dec 12. doi: 10.1038/s41416-023-02526.
    >> Share

    November 2023
  34. ZHAO JL, Antonarakis ES, Cheng HH, George DJ, et al
    Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC).
    Br J Cancer. 2023 Nov 18. doi: 10.1038/s41416-023-02487.
    >> Share

  35. SHEN J, Chowdhury S, Agarwal N, Karsh LI, et al
    Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN.
    Br J Cancer. 2023 Nov 11. doi: 10.1038/s41416-023-02492.
    >> Share

  36. AHMAD AS, Offman J, Delon C, North BV, et al
    Years of life lost due to cancer in the United Kingdom from 1988 to 2017.
    Br J Cancer. 2023;129:1558-1568.
    >> Share

  37. CAMERON JM, Sala A, Antoniou G, Brennan PM, et al
    A spectroscopic liquid biopsy for the earlier detection of multiple cancer types.
    Br J Cancer. 2023;129:1658-1666.
    >> Share

  38. SHEN M, Liu S, Toland A, Hsu EC, et al
    ACAA2 is a novel molecular indicator for cancers with neuroendocrine phenotype.
    Br J Cancer. 2023;129:1818-1828.
    >> Share

    October 2023
  39. FENG X, Zhang Y, Vaselkiv JB, Li R, et al
    Modifiable risk factors for subsequent lethal prostate cancer among men with an initially negative prostate biopsy.
    Br J Cancer. 2023 Oct 28. doi: 10.1038/s41416-023-02472.
    >> Share

  40. TURPIN A, Delliaux C, Parent P, Chevalier H, et al
    Fascin-1 expression is associated with neuroendocrine prostate cancer and directly suppressed by androgen receptor.
    Br J Cancer. 2023 Oct 24. doi: 10.1038/s41416-023-02449.
    >> Share

  41. GULLIVER C, Huss S, Semjonow A, Baillie GS, et al
    Loss of PDE4D7 expression promotes androgen independence, neuroendocrine differentiation and alterations in DNA repair: implications for therapeutic strategies.
    Br J Cancer. 2023;129:1462-1476.
    >> Share

    September 2023
  42. HOU Y, Jiang KW, Wang LL, Zhi R, et al
    Biopsy-free AI-aided precision MRI assessment in prediction of prostate cancer biochemical recurrence.
    Br J Cancer. 2023 Sep 27. doi: 10.1038/s41416-023-02441.
    >> Share

  43. HINNEH JA, Gillis JL, Mah CY, Irani S, et al
    Targeting hyaluronan-mediated motility receptor (HMMR) enhances response to androgen receptor signalling inhibitors in prostate cancer.
    Br J Cancer. 2023 Sep 6. doi: 10.1038/s41416-023-02406.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016